Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 7/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.41 |
| ▸ | KIT | P10721 | 2/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14936065 | 1.00 | ALK (0.42) | ALKGPR119KITGRIA1TLR9 | |
| SCHEMBL12074440 | 0.90 | MEN1 (0.42) | ALKGPR119KITMAPTHTT | |
| SCHEMBL14935609 | 0.90 | MEN1 (0.42) | ALKGPR119KITMAPTHTT | |
| SCHEMBL14935793 | 0.79 | GPR119 (0.42) | ALKGPR119ALDH1A1MAPT | |
| SCHEMBL12073148 | 0.79 | GPR119 (0.42) | ALKGPR119ALDH1A1MAPT | |
| SCHEMBL14936144 | 0.77 | JAK1 (0.47) | ALKGPR119 | |
| SCHEMBL12074202 | 0.77 | JAK1 (0.47) | ALKGPR119 | |
| SCHEMBL9999006 | 0.77 | GPR119 (0.48) | ALKGPR119KITGRIA1 | |
| SCHEMBL18902111 | 0.75 | GPR119 (0.48) | ALKGPR119KITGRIA1 | |
| SCHEMBL14935781 | 0.74 | TRPV1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921373-B2 | Compounds having TRPV1 antagonistic activity and uses thereof | SHIONOGI & CO., LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20130123239-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | PURDUE PHARMA L.P. | 2013-05-16 | — | — | US | disclosed |
| EP-2585446-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | Shionogi&Co., Ltd. (JP) | 2013-05-01 | — | — | EP | disclosed |
| WO-2011162409-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123239-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | TRPV1, TRPA1, TRPV2 | ALK 3911/4885GPR119 84/4885KIT 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.